When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Tuberculosis vaccines - Wikipedia

    en.wikipedia.org/wiki/Tuberculosis_vaccines

    Tuberculosis (TB) vaccines are vaccinations intended for the prevention of tuberculosis. Immunotherapy as a defence against TB was first proposed in 1890 by Robert Koch . [ 1 ] As of 2021, the only effective tuberculosis vaccine in common use is the Bacillus Calmette-Guérin (BCG) vaccine, first used on humans in 1921.

  3. What Doctors Want You to Know About the TB Vaccine - AOL

    www.aol.com/lifestyle/doctors-want-know-tb...

    But the tuberculosis vaccine also has “limited effectiveness,” Dr. Schaffner says. Amesh A. Adalja, M.D., a senior scholar at the Johns Hopkins Center for Health Security, agrees. “It’s ...

  4. M72/AS01E - Wikipedia

    en.wikipedia.org/wiki/M72/AS01E

    M72/AS01 E is an experimental tuberculosis vaccine. If approved, it would be the first vaccine for tuberculosis in more than a century after the BCG vaccine. [1] [2] The vaccine consists of two main ingredients. The antigen part is M72, a recombinant fusion protein derived from the sequences of two M. tuberculosis antigens (Mtb32A and Mtb39A ).

  5. BCG vaccine - Wikipedia

    en.wikipedia.org/wiki/BCG_vaccine

    The Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). [9] It is named after its inventors Albert Calmette and Camille Guérin. [10] [11] In countries where tuberculosis or leprosy is common, one dose is recommended in healthy babies as soon after birth as possible. [9]

  6. Tuberculosis - Wikipedia

    en.wikipedia.org/wiki/Tuberculosis

    In primary TB disease (some 1–5% of cases), this occurs soon after the initial infection. [13] However, in the majority of cases, a latent infection occurs with no obvious symptoms. [13] These dormant bacilli produce active tuberculosis in 5–10% of these latent cases, often many years after infection. [48]

  7. MVA85A - Wikipedia

    en.wikipedia.org/wiki/MVA85A

    MVA85A (modified vaccinia Ankara 85A) is a vaccine against tuberculosis developed by researchers led by Professor Helen McShane at Oxford University. [1] It is a viral vector vaccine and consists of an MVA virus engineered to express the 85A antigen once it infects a host cell. 85A is a cell-wall protein of the tuberculosis bacillus.

  8. Latent tuberculosis - Wikipedia

    en.wikipedia.org/wiki/Latent_tuberculosis

    As such, a person diagnosed with latent TB can safely assume that, even after treatment, they will carry the bacteria – likely for the rest of their lives. Furthermore, "It has been estimated that up to one-third of the world's population is infected with M. tuberculosis, and this population is an important reservoir for disease reactivation."

  9. Why tuberculosis cases have risen in recent years after ... - AOL

    www.aol.com/news/why-tuberculosis-cases-risen...

    Tuberculosis cases ticked up from 2020 to 2022. That's likely a result of reduced access to medical care — and therefore screenings — during the pandemic. Why tuberculosis cases have risen in ...